{"id":"NCT02694328","sponsor":"Alkermes, Inc.","briefTitle":"A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)","officialTitle":"A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-02","primaryCompletion":"2018-11-07","completion":"2018-11-07","firstPosted":"2016-02-29","resultsPosted":"2020-02-10","lastUpdate":"2020-02-10"},"enrollment":561,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"ALKS 3831","otherNames":[]},{"type":"DRUG","name":"Olanzapine","otherNames":[]}],"arms":[{"label":"ALKS 3831","type":"EXPERIMENTAL"},{"label":"Olanzapine","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.","primaryOutcome":{"measure":"Percent Change From Baseline in Body Weight at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Olanzapine","deltaMin":6.59,"sd":0.668},{"arm":"ALKS 3831","deltaMin":4.21,"sd":0.681}],"pValues":[{"comp":"OG001","p":"0.003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":54,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["36305696","36226902"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":276},"commonTop":["Weight increased","Somnolence","Increased appetite","Dry mouth","Waist circumference increased"]}}